NxStage Medical Inc. (NASDAQ:NXTM) reached a new 52-week high during trading on Friday . The stock traded as high as $23.08 and last traded at $22.77, with a volume of 321,092 shares traded. The stock had previously closed at $21.84.

Several research firms recently commented on NXTM. Zacks Investment Research upgraded shares of NxStage Medical from a “hold” rating to a “buy” rating and set a $24.00 target price on the stock in a research report on Wednesday. Piper Jaffray Cos. restated an “overweight” rating and issued a $21.00 price target on shares of NxStage Medical in a research report on Tuesday, May 17th. Canaccord Genuity restated a “buy” rating on shares of NxStage Medical in a research report on Wednesday, May 4th. BTIG Research restated a “buy” rating and issued a $27.00 price target on shares of NxStage Medical in a research report on Tuesday, June 7th. Finally, Wells Fargo & Co. restated a “sell” rating on shares of NxStage Medical in a research report on Thursday, May 5th. Two research analysts have rated the stock with a sell rating and seven have given a buy rating to the company. NxStage Medical has an average rating of “Buy” and an average target price of $24.50.

The company’s market cap is $1.47 billion. The stock’s 50-day moving average price is $19.96 and its 200-day moving average price is $17.71.

NxStage Medical (NASDAQ:NXTM) last issued its quarterly earnings results on Wednesday, May 4th. The medical device company reported ($0.02) EPS for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.03. During the same quarter in the previous year, the business earned ($0.09) earnings per share. The business had revenue of $89.20 million for the quarter, compared to the consensus estimate of $88.40 million. The firm’s revenue was up 12.2% on a year-over-year basis. Analysts expect that NxStage Medical Inc. will post ($0.12) earnings per share for the current fiscal year.

In other NxStage Medical news, SVP Winifred L. Swan sold 6,260 shares of the stock in a transaction that occurred on Thursday, April 14th. The shares were sold at an average price of $16.40, for a total transaction of $102,664.00. Following the transaction, the senior vice president now directly owns 15,734 shares in the company, valued at $258,037.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, President Joseph E. Turk, Jr. sold 1,500 shares of the stock in a transaction that occurred on Thursday, May 12th. The shares were sold at an average price of $17.89, for a total transaction of $26,835.00. Following the transaction, the president now owns 103,280 shares in the company, valued at $1,847,679.20. The disclosure for this sale can be found here.

Other hedge funds and institutional investors have modified their holdings of the company. Jennison Associates boosted its position in shares of NxStage Medical by 12.0% in the third quarter. Jennison Associates now owns 1,049,780 shares of the medical device company’s stock worth $16,555,000 after buying an additional 112,792 shares during the last quarter. State Board of Administration of Florida Retirement System boosted its position in shares of NxStage Medical by 9.0% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 53,686 shares of the medical device company’s stock worth $1,176,000 after buying an additional 4,450 shares during the last quarter. California State Teachers Retirement System boosted its position in shares of NxStage Medical by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 117,165 shares of the medical device company’s stock valued at $2,567,000 after buying an additional 1,869 shares in the last quarter. Rhumbline Advisers boosted its position in shares of NxStage Medical by 8.3% in the fourth quarter. Rhumbline Advisers now owns 68,426 shares of the medical device company’s stock valued at $1,499,000 after buying an additional 5,240 shares in the last quarter. Finally, Lebenthal Lisanti Capital Growth LLC purchased a new position in shares of NxStage Medical during the fourth quarter valued at about $1,080,000.

NxStage Medical, Inc is a medical device company. The Company is engaged in the development, manufacturing and marketing of products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Company’s products include the System One, Streamline Blood Tubing Sets and AV Fistula and Apheresis Needles.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.